DB05858ExperimentalProtein Based Therapies
BI-K0376 is investigated for use/treatment in acne. BI-K0376 is a solid. It is under investigation by Pfizer and has gone through phase I of the clinical trails.
- Mechanism
- Curator reviewed
BI-K0376 has a unique mode of action that makes it extremely selective against the bacteria responsible for acne, Propionibacterium acnes, including those that have become resistant to other antibiotic treatments, whilst sparing normal skin bacterial flora.
- Primary indication
- Investigated for use/treatment in acne.Curator reviewed
- Code names
- BI-K0376
Which companies are running trials of BI-K0376, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account